Compare
Fossil Group, Inc. vs Onto Innovation Inc. vs Cognex Corp vs Tandem Diabetes Care Inc
| Latest fiscal year | Fossil Group, Inc. FOSL | Onto Innovation Inc. ONTO | Cognex Corp CGNX | Tandem Diabetes Care Inc TNDM |
|---|---|---|---|---|
| Year ended | 2026-01-03 | 2026-01-03 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.00B | $1.01B | $994.36M | $1.01B |
| Revenue growth (YoY) | -12.3% | +1.8% | +8.7% | +7.9% |
| Gross margin | 56.1% | 49.7% | 66.9% | 53.8% |
| Operating margin | -1.9% | 13.2% | 16.3% | -18.5% |
| Net margin | -7.7% | 13.6% | 11.5% | -20.2% |
| Net income | -$77.84M | $136.76M | $114.44M | -$204.71M |
| EPS (Diluted) | -$1.45 | $2.78 | $0.68 | -$3.04 |
| Operating cash flow | -$57.90M | $328.31M | $245.51M | -$9.72M |
| Free cash flow | -$60.46M | $299.80M | $236.77M | -$29.67M |
| Cash & equivalents | $95.84M | $346.12M | $262.93M | $90.63M |
| Total assets | $689.25M | $2.37B | $2.02B | $881.11M |
| Total liabilities | n/a | $267.09M | $524.65M | $725.94M |
| Shareholders' equity | $86.78M | $2.10B | $1.49B | $155.17M |
| Return on year-end equity | -89.7% | 6.5% | 7.7% | -131.9% |
| Shares outstanding | 58.35M | 49.70M | 167.00M | 68.29M |
Revenue, most recent five fiscal years
| Fiscal year | Fossil Group, Inc. | Onto Innovation Inc. | Cognex Corp | Tandem Diabetes Care Inc |
|---|---|---|---|---|
| Latest | $1.00B Ended 2026-01-03 | $1.01B Ended 2026-01-03 | $994.36M Ended 2025-12-31 | $1.01B Ended 2025-12-31 |
| 1 year earlier | $1.14B Ended 2024-12-28 | $987.32M Ended 2024-12-28 | $914.51M Ended 2024-12-31 | $940.20M Ended 2024-12-31 |
| 2 years earlier | $1.41B Ended 2023-12-30 | $815.87M Ended 2023-12-30 | $837.55M Ended 2023-12-31 | $747.72M Ended 2023-12-31 |
| 3 years earlier | $1.68B Ended 2022-12-31 | $1.01B Ended 2022-12-31 | $1.01B Ended 2022-12-31 | $801.22M Ended 2022-12-31 |
| 4 years earlier | $1.87B Ended 2022-01-01 | $788.90M Ended 2022-01-01 | $1.04B Ended 2021-12-31 | $702.80M Ended 2021-12-31 |